File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: A novel estrogen-free oral contraceptive pill for women: Multicentre, double-blind, randomized controlled trial of mifepristone and progestogen-only pill (levonorgestrel)

TitleA novel estrogen-free oral contraceptive pill for women: Multicentre, double-blind, randomized controlled trial of mifepristone and progestogen-only pill (levonorgestrel)
Authors
Issue Date2007
PublisherOxford University Press. The Journal's web site is located at http://humrep.oxfordjournals.org/
Citation
Human Reproduction, 2007, v. 22 n. 9, p. 2428-2436 How to Cite?
AbstractBackground: The acceptability and continuation rate of oral contraceptive steroids are limited by unpredictable bleeding and the fear of long-term risks such as breast cancer. By inhibiting ovulation and by altering the receptivity of the endometrium, antagonists of progesterone, such as mifepristone, could be developed as estrogen-free novel contraceptives. Methods: Multicentre, double-blind, randomized controlled trial comparing frequency of amenorrhoea (primary outcome), bleeding patterns, side effects and efficacy in women taking daily 5 mg mifepristone (n = 73) or 0.03 mg levonorgestrel (progestogen-only pill; POP, n = 23) for 24 weeks. Results: More women were amenorrhoeic while taking mifepristone than POP (49 versus 0% P < 0.001), and fewer women bled or spotted for >5 days per month (4 versus 39% P < 0.001). Forty-eight percent of women who took mifepristone for 6 months had cystic glandular dilatation of the endometrium but none showed hyperplasia or atypia. There were no pregnancies in 356 months of exposure in women who used only mifepristone for contraception. Two pregnancies occurred in women taking mifepristone who were also using condoms for dual protection. Conclusions: Daily mifepristone (5 mg) is an effective oral contraceptive pill which has a better pattern of menstrual bleeding than an existing POP (levonorgestrel). © The Author 2007. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/173326
ISSN
2015 Impact Factor: 4.621
2015 SCImago Journal Rankings: 2.271
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorLakha, Fen_US
dc.contributor.authorHo, PCen_US
dc.contributor.authorVan Der Spuy, ZMen_US
dc.contributor.authorDada, Ken_US
dc.contributor.authorElton, Ren_US
dc.contributor.authorGlasier, AFen_US
dc.contributor.authorCritchley, HODen_US
dc.contributor.authorWilliams, ARWen_US
dc.contributor.authorBaird, DTen_US
dc.date.accessioned2012-10-30T06:29:21Z-
dc.date.available2012-10-30T06:29:21Z-
dc.date.issued2007en_US
dc.identifier.citationHuman Reproduction, 2007, v. 22 n. 9, p. 2428-2436en_US
dc.identifier.issn0268-1161en_US
dc.identifier.urihttp://hdl.handle.net/10722/173326-
dc.description.abstractBackground: The acceptability and continuation rate of oral contraceptive steroids are limited by unpredictable bleeding and the fear of long-term risks such as breast cancer. By inhibiting ovulation and by altering the receptivity of the endometrium, antagonists of progesterone, such as mifepristone, could be developed as estrogen-free novel contraceptives. Methods: Multicentre, double-blind, randomized controlled trial comparing frequency of amenorrhoea (primary outcome), bleeding patterns, side effects and efficacy in women taking daily 5 mg mifepristone (n = 73) or 0.03 mg levonorgestrel (progestogen-only pill; POP, n = 23) for 24 weeks. Results: More women were amenorrhoeic while taking mifepristone than POP (49 versus 0% P < 0.001), and fewer women bled or spotted for >5 days per month (4 versus 39% P < 0.001). Forty-eight percent of women who took mifepristone for 6 months had cystic glandular dilatation of the endometrium but none showed hyperplasia or atypia. There were no pregnancies in 356 months of exposure in women who used only mifepristone for contraception. Two pregnancies occurred in women taking mifepristone who were also using condoms for dual protection. Conclusions: Daily mifepristone (5 mg) is an effective oral contraceptive pill which has a better pattern of menstrual bleeding than an existing POP (levonorgestrel). © The Author 2007. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved.en_US
dc.languageengen_US
dc.publisherOxford University Press. The Journal's web site is located at http://humrep.oxfordjournals.org/en_US
dc.relation.ispartofHuman Reproductionen_US
dc.subject.meshAdolescenten_US
dc.subject.meshAdulten_US
dc.subject.meshContraceptive Agents, Female - Administration & Dosage - Adverse Effectsen_US
dc.subject.meshContraceptives, Oral, Synthetic - Administration & Dosage - Adverse Effectsen_US
dc.subject.meshDouble-Blind Methoden_US
dc.subject.meshEndometrium - Drug Effects - Pathologyen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshLevonorgestrel - Administration & Dosage - Adverse Effectsen_US
dc.subject.meshMenorrhagia - Chemically Induceden_US
dc.subject.meshMifepristone - Administration & Dosage - Adverse Effectsen_US
dc.subject.meshOvary - Drug Effects - Physiopathologyen_US
dc.subject.meshUterus - Ultrasonographyen_US
dc.titleA novel estrogen-free oral contraceptive pill for women: Multicentre, double-blind, randomized controlled trial of mifepristone and progestogen-only pill (levonorgestrel)en_US
dc.typeArticleen_US
dc.identifier.emailHo, PC:pcho@hku.hken_US
dc.identifier.authorityHo, PC=rp00325en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1093/humrep/dem177en_US
dc.identifier.pmid17609247-
dc.identifier.scopuseid_2-s2.0-34548104562en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-34548104562&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume22en_US
dc.identifier.issue9en_US
dc.identifier.spage2428en_US
dc.identifier.epage2436en_US
dc.identifier.isiWOS:000250009100011-
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridLakha, F=8644093500en_US
dc.identifier.scopusauthoridHo, PC=7402211440en_US
dc.identifier.scopusauthoridVan der Spuy, ZM=35461457500en_US
dc.identifier.scopusauthoridDada, K=19638325400en_US
dc.identifier.scopusauthoridElton, R=7103338990en_US
dc.identifier.scopusauthoridGlasier, AF=35370179000en_US
dc.identifier.scopusauthoridCritchley, HOD=7006731536en_US
dc.identifier.scopusauthoridWilliams, ARW=35459909100en_US
dc.identifier.scopusauthoridBaird, DT=35371609800en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats